Mar 25 2010
BeaconEquity.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/AEZS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/BeaconEquity
AEterna Zentaris Inc. (AEZS) is a global biopharmaceutical company focused on endocrine therapy and oncology. The Company's product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The products of the Company include Cetrorelix, AEZS-108, Perifosine, Ozarelix, AEZS-112 and AEZS-130. On March 31, 2008, the Company completed the selling of the Company's product Impavido to Paladin Labs Inc. (Paladin). On March 5, 2009, the Company entered into a development, commercialization and license agreement with sanofi-aventis for the development, registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the United States market.
Message Board Search for AEZS: http://www.boardcentral.com/boards/AEZS
In the report, the analyst notes:
"Revenues were $40.2 million for the quarter ended December 31, 2009, compared to $7.2 million for the same quarter in 2008. The significant increase in revenues is due primarily to the Company having recognized the remaining unamortized portion, or approximately $30.4 million, of the upfront payment received from sanofi-aventis as part of its development and marketing agreement for cetrorelix in BPH.
"Updated positive phase 2 efficacy and safety data as well as new survival data for perifosine in combination therapy for relapsed/refractory multiple myeloma, were presented at the American Society of Hematology's annual meeting. Results showed that the overall response rate was 41% and median overall survival was reported at 25 months for all evaluable patients."